SB998 would authorize the President to negotiate trusted trade partner agreements with foreign countries to eliminate duties or other import restrictions on medical goods. The aim is to diversify supplier networks and reduce vulnerability to shocks in emergencies, while promoting cooperation on regulatory practices and protecting intellectual property.
The bill sets criteria for partner selection, requires advance congressional notice and ongoing oversight, and establishes monitoring and enforcement tools to ensure adherence to agreed commitments.
At a Glance
What It Does
The President may negotiate, enter into, and enforce trusted trade partner agreements to reduce or eliminate duties and other barriers on medical goods between the United States and partner countries. Agreements may also harmonize regulatory practices and expand access to procurement markets.
Who It Affects
The Trade Representative, federal health and trade agencies, U.S. manufacturers of medical devices and pharmaceuticals, hospitals and distributors, and foreign partners that meet the criteria for trusted status.
Why It Matters
By diversifying suppliers and enabling faster cross-border movement of essential medical goods, the bill aims to harden the U.S. medical supply chain against future shocks and public health emergencies.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act creates a framework for strengthening the United States’ medical supply chain through formal partnerships with foreign countries. It defines what counts as a medical good and as a trusted trade partner, and it lays out the process for negotiating agreements that would reduce or remove tariffs and other trade barriers on medical goods.
The goal is to broaden the global network of reliable suppliers, ease regulatory friction, and promote cooperation on research, data sharing, and manufacturing capacity. The bill also sets up a governance and oversight regime so Congress can monitor negotiations, review proposed agreements, and ensure that any trade concessions actually bolster national health security and public health.
The Five Things You Need to Know
The bill authorizes the President to negotiate trusted trade partner agreements to eliminate duties on medical goods.
A trusted partner must meet criteria including openness during public health emergencies and strong IP protection.
Notice to Congress before negotiations must occur 60 days in advance; negotiations are reported to Congress every 180 days.
A structured congressional review process (30-day initial review, possible 60/30 extension) governs entry into any agreement.
The Trade Representative monitors compliance post-agreement and can propose actions up to suspending the agreement or providing compensatory trade benefits.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title and Purpose
Section 1 establishes the act’s formal citation as the Medical Supply Chain Resiliency Act and frames the overarching objective: to bolster U.S. national security and public health by diversifying and strengthening the medical supply chain through trusted trade relationships.
Findings and Sense of Congress
Section 2 lays out findings about past supply chain disruptions, the fragmentation of pharmaceutical and medical device production, and the need to diversify trade relationships. The sense of Congress stresses diversification and reliable supply as critical to health security in future emergencies.
Purposes
Section 3 enumerates 12 purposes, including improving resilience, protecting intellectual property, expanding supplier networks, expediting cross-border movement of goods, regulatory cooperation, and enhancing transparency and regulatory harmonization to support trade in medical goods.
Definitions
Section 4 defines key terms (medical goods, medical devices, pharmaceutical goods, trusted trade partner, trusted trade partner agreement, appropriate committees of Congress, and country) to ensure consistent interpretation across negotiations and oversight.
Authority to Enter into Trusted Trade Partner Agreements
Section 5 authorizes the President to negotiate, enter into, and enforce trusted trade partner agreements when it determines such agreements would contribute to national security and public health. It also allows modification of duties to implement these agreements and lists considerations for selecting partner countries.
Congressional Oversight, Notice, Consultations, Access to Information, and Review
Section 6 requires 60-day notice to Congress before negotiations, mandates consultation during negotiations, and specifies access to relevant documents. It also imposes a structured congressional review process before any agreement takes effect, including notice, reporting, and potential delays through resolutions.
Monitoring and Enforcement
Section 7 tasks the Trade Representative with ongoing monitoring of partner compliance and outlines responses if a partner fails to meet commitments, including possible actions by the President to suspend, modify, or seek compensatory benefits, with a 15-day implementation deadline after a decision.
This bill is one of many.
Codify tracks hundreds of bills on Trade across all five countries.
Explore Trade in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- United States Trade Representative and relevant federal agencies benefit from a structured mechanism to diversify supply and coordinate policy,
- U.S. manufacturers of medical devices and pharmaceuticals gain access to expanded procurement markets and potential tariff relief,
- Hospitals, health systems, and distributors benefit from more reliable access to medical goods and smoother cross-border movement,
- Public health authorities and the national security community gain improved resilience planning and data sharing for response readiness,
- Foreign partner governments that meet the criteria gain access to U.S. markets and enhanced collaboration in health security.
Who Bears the Cost
- Negotiating agencies (e.g., USTR, Commerce) incur resource and staffing costs for negotiations, monitoring, and compliance activities.
- Importers and distributors may face compliance costs and supply chain realignment expenses as new agreements come into force.
- Domestic manufacturers may incur costs to meet any new standards associated with trusted partner status and to adjust to changes in competition dynamics.
- Taxpayers could bear indirect costs associated with expanded oversight and staff time dedicated to the review and implementation process.
Key Issues
The Core Tension
The central dilemma is balancing rapid, broad access to medical goods through tariff relief and regulatory alignment with the need to maintain rigorous standards, protect intellectual property, and ensure that partnerships truly enhance national health security without creating new dependencies or market distortions.
The bill creates a proactive, diplomatic pathway to reshape medical goods trade, but it raises policy tensions. Expedited tariff elimination and regulatory harmonization could improve resilience, yet they also risk eroding certain domestic regulatory prerogatives, affecting pricing, competition, and innovation dynamics.
The reliance on trusted partners concentrates leverage in a subset of countries, which could create vulnerability if geopolitical relations shift or if partner performance falters. Implementation will require careful calibration of standards, safeguarding of intellectual property, and ongoing evaluation of whether partnerships deliver real, timely health-security benefits.
Questions remain about measurement, accountability, and the speed at which benefits materialize in practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.